10:20 AM EDT, 10/29/2025 (MT Newswires) -- Zoetis ( ZTS ) said Wednesday the European Commission approved the marketing of its monoclonal antibody therapy Portela for treating pain linked to osteoarthritis in cats.

The company said Portela is the first monoclonal antibody-based treatment approved in the European Union that provides pain relief for three months with a single injection.

The decision follows a recommendation from the Committee for Veterinary Medicinal Products, which found the therapy's safety and effectiveness acceptable based on trial data, according to the company.

Zoetis ( ZTS ) said Portela will join its existing osteoarthritis treatment, Solensia, and is expected to be available in the European Union in 2026.

Price: 145.50, Change: +0.08, Percent Change: +0.06